Usefulness of per-rectal portal scintigraphy with technetium-99m pertechnetate for prognosis of primary biliary cirrhosis.
OBJECTIVE
Conventional methods predicting survival in patients with primary biliary cirrhosis are based on the results of blood tests and on clinical condition, both of which may be affected by treatment. Portal circulation can be evaluated in a relatively noninvasive manner by per-rectal portal scintigraphy. We used this method to evaluate portal hemodynamics and assess prognosis in patients with primary biliary cirrhosis.


METHODS
Per-rectal portal scintigraphy with Tc-99m pertechnetate was done in 51 patients with primary biliary cirrhosis. A solution containing Tc-99m pertechnetate was instilled into the rectum, and serial scintigrams were taken while radioactivity curves for the liver and heart were recorded sequentially. The per-rectal portal shunt index was calculated from the curves.


RESULTS
The shunt index was higher in patients with stage IV primary biliary cirrhosis than in those with stage I, II, or III primary biliary cirrhosis. On the basis of portal shunt index, the patients were divided into those with a shunt index of less than 18%, and those with a shunt index of 18% or more. The cumulative survival rate was lower among patients with the higher shunt index. On regression analysis, the portal shunt index was found to be significantly related to survival.


CONCLUSIONS
Our results indicate that per-rectal portal scintigraphy with Tc-99m pertechnetate can be used to non-invasively evaluate the portal circulation of patients with primary biliary cirrhosis and is useful in establishing prognosis in such patients.
Nishiguchi
Shuhei
S
Department of Hepatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, 545-8585 Osaka, Japan.
Shiomi
Susumu
S
Ishizu
Hirotaka
H
Iwata
Yoshinori
Y
Sasaki
Nobumitsu
N
Tamori
Akihiro
A
Habu
Daiki
D
Takeda
Tadashi
T
Ochi
Hironobu
H
D000285:Administration, Rectal; D001706:Biopsy; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008099:Liver / Q000473:pathology / Q000503:physiopathology; D008105:Liver Cirrhosis, Biliary / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008111:Liver Function Tests; D011168:Portal System / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011169:Portal Vein / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology; D011379:Prognosis; D011877:Radionuclide Imaging; D013670:Sodium Pertechnetate Tc 99m / Q000008:administration & dosage; D016019:Survival Analysis
D013670:Sodium Pertechnetate Tc 99m